Kalaris Therapeutics, Inc.
KLRS
$5.54
$0.071.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.27% | -11.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.96% | 18.37% | |||
| Operating Income | -3.96% | -18.37% | |||
| Income Before Tax | -4.79% | -11.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.79% | -11.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.79% | -11.32% | |||
| EBIT | -3.96% | -18.37% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.79% | 75.87% | |||
| Normalized Basic EPS | -4.80% | 75.87% | |||
| EPS Diluted | -4.79% | 75.87% | |||
| Normalized Diluted EPS | -4.80% | 75.87% | |||
| Average Basic Shares Outstanding | 0.00% | 361.41% | |||
| Average Diluted Shares Outstanding | 0.00% | 361.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||